Who Optimizes SG&A Costs Better? Axsome Therapeutics, Inc. or Supernus Pharmaceuticals, Inc.

SG&A Cost Optimization: Axsome vs. Supernus

__timestampAxsome Therapeutics, Inc.Supernus Pharmaceuticals, Inc.
Wednesday, January 1, 2014139283072471000
Thursday, January 1, 2015241928989204000
Friday, January 1, 20166343648106010000
Sunday, January 1, 20177206691137905000
Monday, January 1, 20189351522159888000
Tuesday, January 1, 201913598030158425000
Wednesday, January 1, 202028896749200677000
Friday, January 1, 202166646205304759000
Saturday, January 1, 2022159253661377221000
Sunday, January 1, 2023323123000336361000
Monday, January 1, 2024411359000
Loading chart...

Unlocking the unknown

Optimizing SG&A Costs: A Tale of Two Biopharma Companies

In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Axsome Therapeutics, Inc. and Supernus Pharmaceuticals, Inc. have taken different paths in optimizing these costs over the past decade.

From 2014 to 2023, Axsome Therapeutics saw a staggering increase in SG&A expenses, growing from a modest 1% of Supernus's 2014 expenses to nearly 96% by 2023. This reflects Axsome's aggressive expansion strategy. Meanwhile, Supernus Pharmaceuticals maintained a more consistent trajectory, with expenses peaking in 2022, indicating a stable yet growth-oriented approach.

Understanding these trends offers valuable insights into each company's strategic priorities. Axsome's rapid increase suggests a focus on scaling operations, while Supernus's steadier growth may indicate a balanced approach to cost management and market expansion.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025